Based on the Silence Therapeutics PLC stock forecast from 5 analysts, the average analyst target price for Silence Therapeutics PLC is USD 27.57 over the next 12 months. Silence Therapeutics PLC’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Silence Therapeutics PLC is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Silence Therapeutics PLC’s stock price was USD 3.70. Silence Therapeutics PLC’s stock price has changed by -5.85% over the past week, +43.97% over the past month and -82.56% over the last year.
No recent analyst target price found for Silence Therapeutics PLC
No recent average analyst rating found for Silence Therapeutics PLC
Company Overview Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. Read Less
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company de...Read More
Frequently Asked Questions About Silence Therapeutics PLC (SLN) Stock
Based on ratings from 5 analysts Silence Therapeutics PLC's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 3 sell and hold ratings.
Unfortunately we do not have enough data on SLN's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for SLN is USD 27.57 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on SLN's stock to indicate if its overvalued.
The last closing price of SLN's stock was USD 3.70.
The most recent market capitalization for SLN is USD 0.12B.
Based on targets from 5 analysts, the average taret price for SLN is projected at USD 27.57 over the next 12 months.
This means that SLN's stock price may go up by +645.17% over the next 12 months.
We can't find any ETFs which contains Silence Therapeutics PLC's stock.
As per our most recent records Silence Therapeutics PLC has 116 Employees.
Silence Therapeutics PLC's registered address is 72 Hammersmith Road, London, United Kingdom, W14 8TH.
You can get more information about it from Silence Therapeutics PLC's website at https://www.silence-therapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Silence Therapeutics PLC (SLN) Stock
Based on ratings from 5 analysts Silence Therapeutics PLC's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, 3 sell and hold ratings.
Unfortunately we do not have enough data on SLN's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for SLN is USD 27.57 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on SLN's stock to indicate if its overvalued.
The last closing price of SLN's stock was USD 3.70.
The most recent market capitalization for SLN is USD 0.12B.
Based on targets from 5 analysts, the average taret price for SLN is projected at USD 27.57 over the next 12 months.
This means that SLN's stock price may go up by +645.17% over the next 12 months.
We can't find any ETFs which contains Silence Therapeutics PLC's stock.
As per our most recent records Silence Therapeutics PLC has 116 Employees.
Silence Therapeutics PLC's registered address is 72 Hammersmith Road, London, United Kingdom, W14 8TH.
You can get more information about it from Silence Therapeutics PLC's website at https://www.silence-therapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SLN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
